Meta-analysis: Sulforaphane reno-protective effects in animal models of kidney diseases
Description
Research question: Does Sulforaphane present any reno-protective effects in pre-clinical animal models of kidney disease ? Context and rationale: Chronic kidney disease (CKD) is characterized by the occurrence of kidney damage and progressive and irreversible loss of kidney function. CKD constitutes an important public health problem worldwide since its prevalence is estimated to be 10-16% in the World’s adult population. Many pharmacological strategies are being studied to improve the clinical picture of these patients and prevent kidney failure. The Keap1-Nrf2 pathway is the major regulator of cytoprotective responses to oxidative and cytotoxic stress. Keap1 (Kelch ECH associating protein 1), a repressor protein binds to Nrf2 and promotes its degradation by the ubiquitin proteasome pathway. The Keap1-Nrf2 pathway have received extensive attention in the context of renal failure. In recent years, clinical studies were performed with bardoxolone methyl, a potent inhibitor of Keap1, that proved to be efficient to prevent the decline of renal function in patients with diabetic kidney disease, but unfortunately trials were stopped due to an increase in cardiovascular mortality. There is therefore a growing interest to find other activator of Nrf2 system. Some natural compounds such as sulforaphane, present in many vegetables such as cruciferous, are potent activator of Nrf2 pathway. Sulforaphane (SFN), a naturally-occurring isothiocyanate enriched in cabbage and broccoli, has been tested in various animal models of kidney failure. This systematic review intends to summarize the knowledges on this field and, if possible, meta-analyze the impact of sulforaphane on renal outcomes especially biomarkers of renal function, in animal models of kidney disease. Evidencing with the highest level of evidence the beneficial effects of sulforaphane on renal function in preclinical models could stimulate the clinical interest for this compound and promote the implementation of clinical trials in patients with kidney failure. The present protocol was pre-registered on the open-access international prospective register of systematic reviews PROSPERO (https://www.crd.york.ac.uk/prospero/) under the registration number # CRD42022364229.
Files
Steps to reproduce
Studies were identified by electronic searching into the following databases: Medline, Clarivate Web of Science, Scopus and Embase. We used the following research equation to search all 4 databases: [sulforaphane AND ( kidney OR renal OR kidney failure OR kidney disease OR kidney injury OR nephropathy)] and whenever available the filter “non human” or “animal study”.
Institutions
Categories
Funding
Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
FAPERJ nº 01/2022 (Programa de mobilidade internacional FAPERJ/França- 2022)